Diagnosis of cancer
AssigneeOwlstone Medical Limited
InventorsMax Allsworth, Edoardo Gaude, Marc van der Schee
Life of this patent
Estimating the term…
Abstract
A method for the early detection and monitoring of the progression of cancer by detecting breath biomarkers is provided. The method comprises assessing the activity of an aldo-keto reductase by measuring the concentration of an exogenous substrate for said enzyme and/or measuring the concentration of a metabolite of said substrate in exhaled breath of a subject. Preferably, the cancer is lung cancer.
Claims22
A method for the detection or prognosis of cancer comprising assessing the activity of an aldo-keto reductase (AKR) by measuring the concentration of an exogenous substrate for said AKR and/or measuring the concentration of a metabolite of said substrate in exhaled breath of a subject, wherein the cancer is lung cancer and where in said AKR is AKR1B10 or AKR1B15.
A method for monitoring the progression of cancer in a subject diagnosed with cancer comprising assessing the activity of an aldo-keto reductase (AKR) by measuring the concentration of an exogenous substrate for said AKR and/or measuring the concentration of a metabolite of said substrate in exhaled breath of the subject, wherein the cancer is lung cancer and wherein said AKR is AKR1B10 or AKR1B15.
A method for determining efficacy of a treatment comprising in a subject diagnosed with cancer assessing the activity of an aldo-keto reductase (AKR) by measuring the concentration of an exogenous substrate for said AKR and/or measuring the concentration of a metabolite of said substrate in exhaled breath of the subject wherein said subject has received anti-cancer treatment, wherein the cancer is lung cancer and wherein said AKR is AKR1B10 or AKR1B15.
A method of treating cancer in a subject comprising assessing the activity of an aldo-keto reductase (AKR) by measuring the concentration of an exogenous substrate for said AKR and/or measuring the concentration of a metabolite of said substrate in exhaled breath of the subject wherein said subject has received anti-cancer treatment, wherein the cancer is lung cancer and wherein said AKR is AKR1B10 or AKR1B15.
A system for the detection of cancer comprising assessing the activity of an aldo-keto reductase (AKR) by measuring the concentration of an exogenous substrate for said AKR and/or measuring the concentration of a metabolite of said substrate in exhaled breath of a subject wherein said system comprises a device for capturing a breath sample from the subject, wherein the cancer is lung cancer and wherein said AKR is AKR1B10 or AKR1B15.
Dependencies are inferred from the claim text.